Literature DB >> 1718809

A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.

F W Leebeek1, C Kluft, E A Knot, M P de Maat, J H Wilson.   

Abstract

The aim of this study was to assess the cause of enhanced fibrinolysis in cirrhosis by studying the balance between profibrinolytic and antifibrinolytic proteins in 24 patients with mild or severe cirrhosis. Antigen levels of both tissue-type plasminogen activator and plasminogen-activator inhibitor 1 were increased in mild and severe cirrhosis. Activity levels showed a very wide variability, but median activity levels of both proteins were normal. In most patients, the increase in tissue-type plasminogen activator was counterbalanced by the increased levels of plasminogen-activator inhibitor 1, but in a subgroup of patients the change in balance resulted in extremely high tissue-type plasminogen-activator levels. The specific activity of both proteins (activity/antigen quotient) was reduced in either mild or severe cirrhosis. This finding indicates either that more enzyme-inhibitor complexes circulate in the blood of patients with cirrhosis than in normal individuals or that dysfunctional molecules circulate. Plasminogen and alpha 2-antiplasmin antigen and activity levels were decreased in both mild and severe cirrhosis. The binding of alpha 2-antiplasmin to fibrin was decreased in severe cirrhosis, making fibrin clots more susceptible to lysis. Clot lysis experiments were performed to see if equal decreases in plasminogen and alpha 2-antiplasmin levels, as found in cirrhosis, result in a change in the rate of fibrinolysis. It was found that the proportionate decreases led to enhancement of fibrinolysis, indicating that the inhibitor depletion is more important than the proenzyme depletion. The authors conclude that enhanced fibrinolysis frequently found in cirrhosis may be attributed to an increased tissue-type plasminogen-activator activity relative to plasminogen-activator-inhibitor activity and decreased levels of alpha 2-antiplasmin, resulting in a reduced binding of alpha 2-antiplasmin to fibrin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718809     DOI: 10.1016/0016-5085(91)90092-y

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

Review 1.  [Coagulation management in patients with liver disease].

Authors:  A Bienholz; A Canbay; F H Saner
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-05-05       Impact factor: 0.840

2.  Hyperfibrinolysis in hepatosplenic schistosomiasis.

Authors:  N E el-Bassiouni; A E el Bassiouny; H R el-Khayat; M M Akl; S A Omran
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

3.  Hyperfibrinolysis.

Authors:  B J Hunt; H Segal
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

4.  Spontaneous gastrocnemius muscle haematoma formation in a patient with alcoholic liver disease.

Authors:  Ndawapeka Tulonga Nhinda; Innocent Lule Segamwenge; Twitileni Nampweya; Chrizelda Engels
Journal:  Pan Afr Med J       Date:  2020-08-26

5.  Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most?

Authors:  Kryssia Isabel Rodríguez-Castro; Alessandro Antonello; Alberto Ferrarese
Journal:  World J Hepatol       Date:  2015-07-18

Review 6.  Venous thromboembolism in cirrhosis.

Authors:  Zhineng J Yang; Karen A Costa; Enrico M Novelli; Roy E Smith
Journal:  Clin Appl Thromb Hemost       Date:  2012-10-17       Impact factor: 2.389

7.  Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.

Authors:  K Leiper; A Croll; N A Booth; N R Moore; T Sinclair; B Bennett
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

Review 8.  Transfusion strategies in patients with cirrhosis.

Authors:  Patricia Liu; Justine Hum; Janice Jou; Richard M Scanlan; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2019-11-19       Impact factor: 2.997

9.  Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest.

Authors:  S Naveau; T Poynard; C Benattar; P Bedossa; J C Chaput
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

10.  The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease.

Authors:  Ton Lisman; Virginia Hernandez-Gea; Maria Magnusson; Lara Roberts; Simon Stanworth; Jecko Thachil; Armando Tripodi
Journal:  J Thromb Haemost       Date:  2021-04       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.